Skip to main content
Premium Trial:

Request an Annual Quote

Daniel Marshak Joins PerkinElmer as CSO; David Tyler to Head QA at ChondroGene; Amir Avniel Tapped as CEO at Rosetta Genomics; and Others

NEW YORK, May 15 (GenomeWeb News) - PerkinElmer has appointed Daniel Marshak as vice president and chief scientific officer. Marshak will be responsible for PerkinElmer's R&D strategy, and for "helping drive its growth strategies in the emerging areas of personalized medicine and predictive diagnostics," the company said in a statement.

 

Marshak joins the firm from Cambrex, where he was vice president and CTO. He currently serves as an adjunct associate professor at Johns Hopkins University School of Medicine and is also an advisor to PharmaFrontiers.

 

Marshak holds a PhD from RockefellerUniversityand a BA in biochemistry and molecular biology from HarvardUniversity.

 


ChondroGene has hired David Tyler as director of product development and quality assurance.

 

Tylermost recently worked at Prodesse and Third Wave Technologies, where he managed product development and GMP manufacturing operations and helped both firms obtain ISO 13485 certification.

 

Tyler has also held research and management positions at the Howard Hughes Medical Institute at the University of California, Berkeley; the University of California, San Francisco; and Lawrence Berkeley National Laboratory. He has a BA in biochemistry and an MS in microbiology from UC Berkley.

 


Israel Stein has stepped down as president and CEO of Clinical Data to become executive vice chairman, while Drew Fromkin, previously executive vice president of Clinical Data and president of the company's PGxHealth division, will now serve as president and CEO.

 

Stein will serve as interim CFO, replacing Mark Shooman. 

 

Clinical Data disclosed the management changes  earlier today, along with plans to spin out its investigational antidepressant drug vilazodone into a new company.

 


Amir Avniel has been named president and CEO of Rosetta Genomics, while Nathan Hod has joined the company's board of directors and Yoav Chelouche has been elected to serve as the new chairman of the board.

 

Avniel joined the company in 2000 and was formerly president, CTO, and COO.

 

Chelouche has been a member of the Rosetta Genomics board of directors since 2001, and is currently a managing partner at Aviv Venture Capital. He previously served as president and CEO of Scitex.

 

Hod co-founded DSPC, a manufacturer of chip sets for the wireless industry that was acquired by Intel in 1999.

 


Robert Forbes Burns has joined Celldex as CEO. Prior to joining the company, Burns was director of the office of technology licensing at the Ludwig Institute for Cancer Research.

 

Prior to that, Burns was commercial director at Oxford GlycoSciences, and held senior executive positions at British Biotechnology, Applied BioTechnology, Ciba-Corning Diagnostics, and Corning Diagnostics.

 

Burns is also a non-executive director of Lymphatix of Helsinki, Finland.

 


Marnie MacDonald has left Odyssey Thera, Cell-Based Assay News, a GenomeWeb News sister publication, reported last week. MacDonald was president and CEO of the company since 2002. Prior to that, MacDonald served as chief business officer for the company. Odyssey declined to comment on the reason for MacDonald's departure.

 

John Westwick is the current president and chief scientific officer, according to the company's website. It is unclear whether the company has named an interim or new CEO. Westwick joined Odyssey in 2003 as vice president of drug discovery.

 


Cell-Based Assay News also reported that Dietrich Ruehlmann has left BD Biosciences and joined New Zealand Trade & Enterprise, a government organization that assists New Zealandbiotechnology companies in commercial endeavors.

 

Ruehlmann was formerly product manager for imaging and analysis in the bioimaging systems division of BD Biosciences, based in Rockville, Md.

 


Sean Ekins has joined Arnold Consultancy and Technology, a pharmaceutical consulting firm based in New York, as senior vice president of computational biology, BioInform, a GenomeWeb News sister publication, reported last week. Ekins most recently served as vice president for computational biology at GeneGo. Prior to that, he was associate director for computational drug discovery at Concurrent Pharmaceuticals. Ekins holds a PhD from the Universityof Aberdeenin the UK.

 


Frederick Schmid has joined Panacos Pharmaceuticals as senior vice president of commercial operations and business development.

 

Schmid most recently served as vice president of sales and marketing for virology/HIV at Roche Laboratories. Prior to that, he was executive director of HIV marketing at GlaxoSmithKline.

 

Schmid holds a DVM from Iowa State University College of Veterinary Medicine and an MBA from the Universityof North Carolinaat Chapel Hill.

 


Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.